Subsequent application of Ki-67 immunohistochemistry in SMS-CTR xenograft showed a dose-dependent decrease in nuclear expression suggesting a possible decrease in tumor proliferation in response to tipifarnib (Fig. 4i and Supplemental Fig. 5). Here, MKI67 is linked to neoplasm.